Developing POC Tests for Alzheimer’s to Improve Monitoring and Management of the Disease
By LabMedica International staff writers Posted on 22 Mar 2016 |

Image: Illustration of a protocol showing a pathway to develop core-shell nanoparticle/hybrid graphene oxide based multi-functional platform label-free SERS detection of β-amyloid toward developing a portable point-of-care blood test to monitor Alzheimer’s disease progression (Figure courtesy of Teresa Demeritt et al., 2015, ACS Appl. Mater. Interfaces; Copyright ACS-2015).
Toward development of a portable point-of-care (POC) biosensor for Alzheimer’s disease (AD), a new review explores recent advancements in nano-enabling electrochemical beta-amyloid (β-A) -sensing technologies. A simple, rapid POC biomarker test could greatly improve AD management and personalized treatment, also in developing countries.
The authors of the review, from the College of Medicine at Florida International University (Miami, FL, USA), are taking a new approach to diagnosing AD: measuring β-A in the blood with a POC test. AD is caused by high levels of β-A in the brain that lead to degeneration of brain cells. Various types of scans and immunoassays, such as MRI and ELISA, are available to estimate β-A levels in the brain. But the peptide can also be found at lower levels in blood, making it a useful biomarker for a simple test.
Currently there is no sensitive or inexpensive way to measure β-A levels in blood samples. The authors of the new review plan to change that. “We want to develop a point-of-care system where a small drop of blood plasma can reveal their β-A level immediately so that a doctor can tailor a patient’s therapy immediately,” said lead author Dr. Ajeet Kaushik, “The drugs used to treat AD can have side effects, so it’s better for patients not to overdose. With the right data, doctors can respond quickly to changes in a patient’s brain by reducing or increasing their dose.”
In the review, Dr. Kaushik and colleagues looked at each of the methods available to measure β-A concentration in brain tissue and in blood. None of the existing tests can be done at the bedside and all need special expertise and large samples. They also take a long time to generate a useful result—the main existing test, an ELISA, takes 6–8 hours. In comparison, the cheap, simple biosensor Dr. Kaushik and colleagues describe can measure β-A in the blood at low (pico molar) concentrations in just 30 minutes.
“Even though existing technologies are well established, we need to move towards small sample, high accuracy tests that can be used in all environments, from developed countries to rural settings. Our goal is to develop a test that’s sensitive, small, and affordable,” said Dr. Kaushik. To develop the new biosensor, the team will need many bio-fluid samples taken at different stages of the disease. Finding these samples will be challenging, but the review demonstrates that a biosensor is achievable. Such a test would also “show if and when the disease reaches an untreatable level. In the future we hope a rapid biosensor test for AD will help scientists study disease progression and help clinicians deliver personalized therapy to patients.”
The study, by Kaushik A et al., was published online ahead of print January 28, 2016, in the journal Biosensors and Bioelectronics.
Related Links:
Florida International University
The authors of the review, from the College of Medicine at Florida International University (Miami, FL, USA), are taking a new approach to diagnosing AD: measuring β-A in the blood with a POC test. AD is caused by high levels of β-A in the brain that lead to degeneration of brain cells. Various types of scans and immunoassays, such as MRI and ELISA, are available to estimate β-A levels in the brain. But the peptide can also be found at lower levels in blood, making it a useful biomarker for a simple test.
Currently there is no sensitive or inexpensive way to measure β-A levels in blood samples. The authors of the new review plan to change that. “We want to develop a point-of-care system where a small drop of blood plasma can reveal their β-A level immediately so that a doctor can tailor a patient’s therapy immediately,” said lead author Dr. Ajeet Kaushik, “The drugs used to treat AD can have side effects, so it’s better for patients not to overdose. With the right data, doctors can respond quickly to changes in a patient’s brain by reducing or increasing their dose.”
In the review, Dr. Kaushik and colleagues looked at each of the methods available to measure β-A concentration in brain tissue and in blood. None of the existing tests can be done at the bedside and all need special expertise and large samples. They also take a long time to generate a useful result—the main existing test, an ELISA, takes 6–8 hours. In comparison, the cheap, simple biosensor Dr. Kaushik and colleagues describe can measure β-A in the blood at low (pico molar) concentrations in just 30 minutes.
“Even though existing technologies are well established, we need to move towards small sample, high accuracy tests that can be used in all environments, from developed countries to rural settings. Our goal is to develop a test that’s sensitive, small, and affordable,” said Dr. Kaushik. To develop the new biosensor, the team will need many bio-fluid samples taken at different stages of the disease. Finding these samples will be challenging, but the review demonstrates that a biosensor is achievable. Such a test would also “show if and when the disease reaches an untreatable level. In the future we hope a rapid biosensor test for AD will help scientists study disease progression and help clinicians deliver personalized therapy to patients.”
The study, by Kaushik A et al., was published online ahead of print January 28, 2016, in the journal Biosensors and Bioelectronics.
Related Links:
Florida International University
Latest Pathology News
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
- Advances in Monkeypox Virus Diagnostics to Improve Management of Future Outbreaks
- Nanoneedle-Studded Patch Could Eliminate Painful and Invasive Biopsies
- AI Cancer Classification Tool to Drive Targeted Treatments
- AI-Powered Imaging Enables Faster Lung Disease Treatment
- New Laboratory Method Speeds Diagnosis of Rare Genetic Disease
- New Technology Autonomously Detects AI Hallucinations in Digital Pathology
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. The symptoms of Lyme disease, such as fever, headache, fatigue,... Read more
Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
Detecting and diagnosing cancer, particularly in its early stages, remains a significant challenge. Liquid biopsies offer a promising non-invasive alternative to traditional biopsies, which require removing... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more
AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases
The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. These gut bacteria produce a variety of metabolites... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more